Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects
- 1 August 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 324, 522-531
- https://doi.org/10.1016/j.jconrel.2020.05.036
Abstract
No abstract availableFunding Information
- Research Foundation for Pharmaceutical Sciences (16H05114)
- Japan Society for the Promotion of Science (KAKENHI 15H04758)
- Takeda Science Foundation
This publication has 40 references indexed in Scilit:
- Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319PLOS ONE, 2013
- Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 DiabetesPLOS ONE, 2012
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinomaBMC Cancer, 2012
- FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesisGenes & Development, 2012
- Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in VivoEndocrinology, 2011
- Albumin fusion of thioredoxin — The production and evaluation of its biological activity for potential therapeutic applicationsJournal of Controlled Release, 2010
- Hepatic FGF21 Expression Is Induced at Birth via PPARα in Response to Milk Intake and Contributes to Thermogenic Activation of Neonatal Brown FatCell Metabolism, 2010
- Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese MiceDiabetes, 2009
- FGF-21 as a novel metabolic regulatorJCI Insight, 2005